

S 3250

DHS Opioid Detection Resilience Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: Feb 4, 2020

Current Status: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

Latest Action: Read twice and referred to the Committee on Homeland Security and Governmental Affairs. (Feb 4, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/3250>

Sponsor

Name: Sen. Cornyn, John [R-TX]

Party: Republican • **State:** TX • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Rosen, Jacky [D-NV]	D · NV		Feb 4, 2020
Sen. Cassidy, Bill [R-LA]	R · LA		Jul 30, 2020
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Sep 8, 2020
Sen. Kennedy, John [R-LA]	R · LA		Dec 8, 2020

Committee Activity

Committee	Chamber	Activity	Date
Homeland Security and Governmental Affairs Committee	Senate	Referred To	Feb 4, 2020

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
116 HR 4761	Related bill	Dec 23, 2020: Became Public Law No: 116-254.

DHS Opioid Detection Resilience Act of 2020

This bill establishes new requirements related to the detection of illicit narcotics at ports of entry.

Specifically, U.S. Customs and Border Protection (CBP) must implement a strategy to ensure chemical screening devices are able to identify narcotics at purity levels equal to or less than 10%, or provide an alternate method for identifying narcotics at lower purity levels. The CBP must also test new chemical screening devices at various purity levels before it commits to their acquisition.

Additionally, the Department of Homeland Security must implement a plan for the long-term development of a centralized spectral database for chemical screening devices.

Actions Timeline

- **Feb 4, 2020:** Introduced in Senate
- **Feb 4, 2020:** Read twice and referred to the Committee on Homeland Security and Governmental Affairs.